Overall, in 2017, China’s medical technology and medical device market is expected to exhibit the following key development trends:

　　 1. The full implementation of the two-invoice system is driving channel transformation.

　　In 2017, the two‑invoice system will transition from last year’s pilot phase to full implementation. Large enterprises will deepen their distribution channels, while small and medium‑sized distributors will face elimination, consolidation, or transformation. Under this trend, the industry will give rise to three major structural shifts: horizontal acquisitions, vertical integration, and strategic transformation.

　　In the realm of horizontal acquisitions, large commercial enterprises with ample capital, strong financial resources, and extensive distribution networks will continue to acquire and consolidate regional channels, transforming these channels into providers of end-to-end supply-chain integration solutions, thereby driving explosive growth in their performance.

　　Vertical integration can be categorized into three types: first, downstream channelization among manufacturing firms, where large enterprises acquire distributors—for example, Meikang acquired Yitian Bio, and Antu acquired Shengshi Junhui; second, upstream self‑production by distribution‑focused companies, whereby distributors acquire upstream technologies—such as Runda Medical, which originated in the distribution sector, acquiring a POCT product line with high technological barriers; and third, downstream service‑orientation, as distribution firms extend their reach to end‑user services—for instance, Dian Diagnostics continues to proactively expand its network of third‑party clinical laboratories at the point of care. Vertical integration grants firms greater influence across the value chain, thereby enhancing profitability through synergistic effects.

　　Transformation refers to the shift in business models between medical device manufacturers and channel‑oriented companies. For example, some medical device distributors are transitioning into CSOs under the backdrop of the two‑invoice system, the VAT reform, and broader regulatory crackdowns; meanwhile, certain commercial entities that currently operate as agency‑based distributors may, in response to these developments, pivot toward distribution‑focused business models.

　　In short, the mergers, expansions, and transformations of channel distributors will gradually lead to greater concentration in the distribution sector—this represents the future path for channel consolidation under the two‑invoice system.

　 　2. Tiered healthcare delivery creates opportunities for domestic medical devices.

　　In 2017, the tiered medical‑care reform will continue to deepen and be rolled out nationwide. Although patient attitudes are unlikely to shift quickly, as the saying goes, “ducks are the first to sense the warming of the spring river,” the reform will drive a reallocation of medical resources toward the grassroots level. Unlike China’s high‑end medical‑equipment market, which remains dominated by foreign firms, the vast grassroots healthcare sector has long been a fertile ground for domestic brands. Moreover, policy measures actively encourage and support primary‑care institutions in adopting superior domestically produced medical devices and equipment. We anticipate that, with favorable policies and targeted investment, leading domestic brands—whether well‑established companies with robust distribution networks and product portfolios or emerging innovators with cutting‑edge technologies—will experience explosive growth at the grassroots level.

　　In this context, on the one hand, there is an opportunity to upgrade and modernize existing grassroots‑level equipment; on the other hand, there is a chance to introduce devices that can meet the growing demands of primary healthcare while remaining easy to operate. We will focus on grassroots‑level medical equipment, including diagnostic testing devices—particularly POCT and rapid‑testing systems—home‑use devices for chronic disease management, medical rehabilitation equipment, physician‑led follow‑up and monitoring tools, as well as safe and user‑friendly imaging modalities such as ultrasound.

　 　3. Third-party services based on medical devices are flourishing.

　　As healthcare reform deepens and new models continue to be explored, we believe that an increasing number of institutions and companies will recognize that a “mutually beneficial model”—one that serves hospitals and creates shared value—better aligns with today’s healthcare business landscape than a “disruptive model” that seeks to overhaul hospitals or seize their market share. Under this paradigm, third-party service providers centered on medical devices stand to thrive, and various “Internet Plus”‑based approaches and business models will increasingly integrate into these offerings.

　　In October 2016, the National Health and Family Planning Commission issued the “Notice on the Basic Standards and Management Specifications for Medical Laboratory Testing Laboratories (Trial),” which stipulated that medical laboratory testing laboratories are independently established medical institutions, operating as independent legal entities and assuming corresponding legal liabilities, with establishment and approval vested in the provincial health and family planning administrative departments. Subsequently, in January 2017, the same commission released the “Interpretation of the Basic Standards and Management Specifications for Independently Established Medical Institutions, Including Medical Imaging Diagnostic Centers,” which underscored that establishing medical imaging, laboratory testing, blood purification, and pathology centers as independent medical institutions is imperative.

　　The support expressed in the National Health and Family Planning Commission’s policy documents for third-party diagnostics, imaging, and pathology, coupled with the strategic deployments and M&A activities of major healthcare companies in these areas, indicates that emerging, highly integrated service models—centered on medical devices and equipment, including third-party diagnostics, imaging, pathology, logistics, sterilization, maintenance, and equipment packaging—will significantly drive the development of the healthcare sector. Given that these fields are also capital-intensive, we can expect a substantial wave of investment and M&A activity.

　　In the third-party diagnostics sector, industry leader Kingmed Diagnostics is poised to go public, while emerging players such as Qianmai Medical and Beijing Hehe continue to attract robust capital investment and achieve rapid growth. In the third-party imaging space, Yimai Yangguang has secured Series A funding from Goldman Sachs, while Ping An Good Doctor and the listed company Guangyu Group (002133) are also actively expanding their presence in this field. In the disinfection sector, Laoke Medical and Sinopharm Holdings are vigorously developing third-party disinfection supply chains. Meanwhile, third-party maintenance firms like Kunya Medical and Kedu Medical have respectively listed on the New Third Board and garnered significant capital investment.

　　We have also observed that third-party entities—such as independent diagnostic laboratories and imaging centers—not only provide services to hospitals but can also serve the broader consumer market. By integrating with early‑screening and health‑checkup offerings, they can transcend the confines of the hospital‑centric healthcare ecosystem and unlock a health‑care market worth trillions of yuan. Furthermore, when combined with “Internet Plus” technologies like big data and artificial intelligence, or aligned with areas such as new‑drug development, these initiatives hold immense, untapped potential for explosive growth.

　　 4. New technologies are penetrating the medical device sector.

　　Early‑screening technologies, artificial intelligence, 3D printing, and medical robots (300024), among others, are poised to usher in a disruptive revolution in diagnosis and treatment.

　　Currently, early screening can be broadly categorized into two types: genetic disease screening and cancer screening. Genetic disease screening typically refers to prenatal testing and the use of genetic assays to estimate the likelihood of inheriting a genetic disorder, while cancer screening involves the early detection of tumors—before clinical symptoms appear—through methods such as liquid biopsies and genomic sequencing. Both approaches play a crucial role in enhancing population health and improving cancer survival rates. Recently, the cancer‑early‑detection company Grail secured $900 million in Series B funding, reigniting investor interest. The importance of early screening is self‑evident, and with the integration of technologies like AI‑based diagnostics, it is poised to give rise to a trillion‑dollar blue‑ocean market.

　　In the field of AI‑driven diagnostics, the integration of artificial intelligence with medical imaging has become a major focus in recent years. Last year, the volume of medical images in China and the United States grew by 30% and 63%, respectively, while the number of radiologists increased by only 4.1% and 2.2%, respectively, resulting in a substantial supply‑demand gap in radiological diagnosis. Emerging trends in AI‑assisted image interpretation could fundamentally reshape future imaging diagnostics, addressing the limitations of human‑performed assessments in both quantity and accuracy. Currently, an AI system developed by researchers at Google Brain and Verily has achieved an 88.5% diagnostic accuracy for breast cancer, surpassing the 73.3% accuracy of renowned human pathologists. As AI‑based diagnostics expand to cover additional disease categories and continue to improve in precision, they will align seamlessly with the rapid growth of the third‑party imaging sector, positioning cloud‑based imaging platforms as the ultimate solution for diagnostic imaging.

　　3D‑printed medical devices represent another emerging field. In recent years, the 3D‑printing industry for orthopedic implants has begun to see practical applications, such as Stryker’s 3D‑printed knee replacements, ConMed’s 3D‑printed hip joints, and Kaita Med’s 3D‑printed spinal implants. Another major application area is dentistry: leading international players like BEGO and Planmeca have launched 3D‑printing equipment tailored for oral‑dental use, while companies such as 3D Systems and EOS are also gradually being introduced into Chinese hospitals. Technological advancement will undoubtedly drive the evolution of the medical device market.

　　In 2016, the global medical robotics industry generated approximately US$8.5 billion in revenue. Conservative estimates project an average annual compound growth rate of 15% over the next five years, with total revenues exceeding US$15 billion by 2020. Within this market, surgical robots are expected to account for 60%, while rehabilitation robots will represent 20%. Among surgical robots, the da Vinci system has successfully performed over one million complex procedures since its approval. Meanwhile, rehabilitation robots are steadily gaining market traction thanks to incremental technological advances; according to projections by the University of Michigan’s Rehabilitation Robotics Association, they are forecast to achieve a 37% CAGR over the next five years—far outpacing other segments of the medical robotics sector. In this space, foreign companies such as ReWalk, Cyberdyne, Hocoma, and Woodway have already introduced their exoskeleton robots, while Chinese firms—including Diehe Technology, Fourier Robotics, and Anyang Shenfang—have also begun deploying domestically developed rehabilitation devices.

　　At present, companies developing these cutting-edge technologies in the medical device sector remain in their early stages, with funding still concentrated primarily in pre‑A and Series A rounds. This year, we anticipate a growing number of startups and investment activity across these areas, while leading players are beginning to emerge. Whether platform‑based firms or vertically focused companies will prevail, or whether large corporations’ innovation units or small startups will take the lead, remains to be seen. We believe that platform‑oriented companies should be evaluated on their ability to scale and execute, vertical‑domain firms on their channel‑building and go‑to‑market capabilities, corporate innovation arms on their capacity for collaboration and resource integration, and small startups on their ability to achieve breakthroughs in specific technological areas.

　　5. Precision medicine is gradually transitioning from a conceptual framework to clinical maturity.

　　In January 2015, then‑U.S. President Barack Obama unveiled the “Precision Medicine Initiative,” and the term “precision medicine” gradually became a buzzword in the medical field. With the continued maturation of technologies such as next‑generation sequencing (NGS), gene editing, DNA capture, and bioinformatics, precision medicine has steadily evolved from a conceptual framework into a clinically viable approach. From a clinical workflow perspective, precision medicine can be divided into early screening, disease diagnosis, and post‑treatment monitoring.

　　Leading companies in the field of genetic early‑screening are largely taking shape: Berry and Kang is poised to list on the capital markets, Novogene has secured substantial funding from SDIC Innovation, and Annoroad’s NextSeq 550AR gene sequencer, along with its fetal chromosomal aneuploidy detection kit, have both received CFDA medical device registration approval. In the realm of cancer early‑screening, Grail recently closed a $900 million Series B round, reigniting investor interest. The importance of early screening is self‑evident; in the future, when combined with AI‑driven diagnostics and other technologies, it could unlock a trillion‑dollar blue‑ocean market. Meanwhile, Professor Zhang Kun, one of the founders of Geneseeq, and his team have published their latest breakthrough in Nature Genetics, pioneering a high‑throughput, non‑invasive methylation‑based detection technology that holds promise for non‑invasive cancer early‑screening and tumor origin tracing. Domestically, BorCheng’s colorectal‑cancer methylation‑based early‑screening product has also obtained CFDA medical device approval. These advances are set to fuel industry momentum, with expectations that a wave of start-ups will emerge in this space. Technologically, the development of early‑screening hinges on liquid biopsies, DNA capture and amplification, and the discovery of novel biomarkers such as methylation—while robust clinical data and clear clinical indications are essential to gradually establish these approaches as the gold standard for early detection.

　　In the realm of disease diagnosis, precision medicine is currently most widely applied to precision drug therapy and follow-up care for cancer. By leveraging molecular pathology assays—such as next-generation sequencing (NGS), first‑generation sequencing, PCR, FISH, circulating tumor cell (CTC) analysis, and single‑cell sequencing—clinicians can elucidate patients’ individualized molecular profiles, enabling the development of tailored treatment strategies and prognostic assessments. Combined with targeted therapies and cellular treatments, this approach facilitates precise, personalized care.

　　At present, the domestic NGS and ctDNA sectors are fiercely competitive, with numerous companies vying for market share. Following two years of rapid expansion, the industry is on the cusp of a major reshuffle and increasingly intense competition. We anticipate that, in the short term, the sector will hinge on each company’s business development and commercialization capabilities; in the medium term, on service quality, R&D and regulatory‑approval expertise, and customer retention; and in the long term, on the accumulation and application of big data, the cultivation of a robust commercial ecosystem, and the development and commercialization of cutting‑edge technologies. Among players, established leaders such as Shihe Gene and Burning Rock Medical continue to attract significant capital attention, while emerging forces—including Yuanma Gene, MyGenetics, GenePlus, and Zhenhe Technology—are steadily closing the gap, each carving out its own distinct niche.

　 　6. Overseas investment and M&A activity remains robust.

　　Since the end of 2016, investment firms and large corporations in the medical‑device sector have prioritized stability, focusing on opportunities that deliver sales‑driven profitability and are anchored by well‑established distribution channels. At the same time, they have actively sought to invest in overseas companies with cutting‑edge technologies, aiming to introduce new products while leveraging domestic channel strengths to create complementary synergies. Given that, overall, the commercialization cycle for medical devices is shorter than that for new drugs, we expect investment firms—particularly U.S. dollar‑denominated funds—to maintain this trend this year, further increasing their investments in, and even pursuing acquisitions of, overseas technology‑driven medical‑device companies. Meanwhile, A‑share‑listed companies will continue to acquire overseas medical‑device firms, as cross‑border M&A has become an effective pathway for domestic players to gain access to foreign technologies and for international companies to establish a foothold in the Chinese market.

　　Since 2016, Jiuan Medical has acquired eDevice for €93.88 million, bolstering its presence in medical diagnostic equipment; Zixing Pharmaceutical acquired Nabsys 2.0, entering the genetic testing market; BOE Technology invested $50 million in Cnoga, an Israeli non-invasive medical device company; and Sanovo Biotech spent $200 million to acquire U.S.-based PTS Diagnostics, expanding into the POCT segment of the IVD industry. In vitro diagnostics, gene sequencing, and innovative medical devices—high‑tech, fast‑growing sectors with significant barriers to entry—are prime targets for leading companies’ M&A activity. 2017 is poised to be another year in which domestic industry leaders vie to establish a foothold overseas.